National and Kapodistrian University of Athens
Κλινική αξιολόγηση και μελέτη της L-Dopa αποκαρβοξυλάσης και του νέου αποπτωτικού γονιδίου BCL2L12 στο γαστρικό καρκίνο
Abstract
dc:descriptionGastric cancer belongs among the most lethal malignant neoplasms, with its frequency to exhibit wide geographical distribution, worldwide. Stomach tumours of the first stages are often asymptomatic, fact which delays their early diagnosis. Consequently, by the time of their diagnosis, locally advanced or metastatic tumours are practically inoperable, thus rendering patients’ cure not feasible. Despite the identification of a number of possible cancer biomarkers, their overall utility in stomach cancer remains fragmentary. Although the percentage of patients’ survival, with gastric tumours, has escalated, high mortality levels still predominate. Therefore, the discovery of new molecular indicators for the early diagnosis, prognosis and prediction of response to therapeutic treatment, in gastric cancer, is of exquisite importance. After intensive research studies, it has become evident that deregulation of apoptosis exerts a drastic role in the development or progression of various human malignancies. The apoptotic genes seem to be involved in the transformation of normal gastric epithelium to the corresponding with α malignant phenotype. Relatively recent was the identification and cloning by Scorilas et al., of the BCL2L12 (BCL2-like 12) gene, which belongs to the BCL-2 apoptotic genes’ family. The BCL2L12 gene has been localized at the chromosomal locus 19q13.3, at a close proximity to the already known genes IRF3 and RRAS that are related to carcinogenesis. Except for the classical transcript of the BCL2L12 gene, two additional alternative transcripts have been described, the BCL2L12-A lacking exon 3 and one isoform which possesses three nucleotides less than the classical transcript. The mRNA expression levels of BCL2L12 have been studied in the human malignancies of the breast, colon and glioblastoma. Important modulations in the mRNA expression of the gene have been noticed in a variety of cancer cell lines following their exposure to several cytotoxic drugs. The DDC gene maps to the chromosomal region 7p12.2 and codes for the enzyme L-Dopa decarboxylase which participates, mainly, in the decarboxylation of L-3,4 dihydroxy-phenylalanine (L-Dopa) to dopamine. Up to date, four different transcripts of the gene have been identified, which constitute products of alternative splicing events: one ‘‘neural-type’’, a second one of ‘‘non-neural type’’, one transcript lacking exon 3 and the Alt-DDC mRNA that includes an alternative exon 10. Enhanced mRNA expression of the DDC gene, as well as, elevated activity of the enzyme have been observed in tumours of neuroendocrine origin. In the case of solid tumours, such as colon and prostate carcinomas, DDC mRNA overexpression has been associated with the diagnosis and the prognosis of these types of cancer. High DDC mRNA levels have been detected in gastric cancer cells’ micrometastases to the peritoneal cavity. In the present PhD thesis, the genes BCL2L12 and DDC were studied and clinically evaluated in primary tumours of the stomach. Furthermore, their utility as possible tumour markers for the early prognosis and accurate staging of the disease, as well as, for the prediction of patients’ response to the selection of the appropriate chemotherapeutic treatment, was investigated. Particularly, in parallel with the collection of the 80 gastric tissue specimens, the construction of a detailed database was performed, which included each patient’s full medical history for an extensive subsequent biostatistical analysis. An outline of the experimental processes regarded tissue homogenization of a statistically significant sample size of the collected tissue specimens, total RNA isolation and cDNA synthesis. The mRNA expression of the genes BCL2L12 and DDC was examined, qualitatively, with regular-PCR, while for their quantification, qReal-time PCR methodology was developed by exploiting the SYBR Green I chemical detection system. Having isolated total protein and having determined its concentration with the Bradford assay, analysis and study of the full-length DDC protein, with Western immunoblotting, was conducted in gastric tissue samples. Additionally, the activity of the DDC enzyme was also explored towards the decarboxylation of L-Dopa to dopamine. The effect of the cytotoxic substances doxorubicin, epirubicin, oxaliplatin and methotrexate on the viability of the cancer cell line, AGS, from stomach adenocarcinoma was looked at with the MTT assay. Afterwards, BCL2L12 and DDC mRNA expression was qualitatively analyzed (with regular-PCR) and quantitatively determined (with qReal-time PCR) in the treated-AGS cells compared with the control-cells of each corresponding time interval. The results from the qualitative analysis illustrated differences in the mRNA expression of the two target-genes both in cancerous and in non-cancerous (normal) gastric tissue samples. Following the statistical analysis of the data obtained from real-time polymerase chain reaction methodology, significantly elevated BCL2L12 expression was found in the stomach adenocarcinomas of the early TNM stages and also in those tumours histologically categorized as intestinal-type. Correlation of the expression of the DDC gene with the clinicopathological features of the patients revealed statistically significant increased mRNA levels of the gene in stomach carcinomas of the intestinal histological type and in those neoplasms located at the lower third part of the stomach. Kaplan Meier survival analyses demonstrated that patients with gastric tumours, in which the expression of the genes BCL2L12 and DDC was increased and above the cutoff point, displayed better overall survival and experienced lower risk for recurrences as opposed to patients whose neoplasms did not express these particular genes. Therefore, we propose the possible use of BCL2L12 and DDC as independent and favourable prognostic indicators with a statistically significant strenght for the disease free survival (DFS) and the overall survival (OS) of gastric cancer patients. Although, small fluctuations of the DDC protein levels were documented between the cancerous stomach specimens, the enzyme did not seem to be active towards the decarboxylation of L-Dopa to dopamine. The study of the molecular changes, at the mRNA level, of the genes BCL2L12 and DDC in the gastric cancer cell line AGS, disclosed remarkable alterations after cells’ incubation with the prementioned anticancer drugs. These particular findings showed that, on their majority, the levels of these two genes were significantly diminished following the addition of one of the four antineoplastic substances in the AGS cells in comparison to the untreated control cells (without drug). The declining tendency, viewed at the mRNA levels of BCL2L12 and DDC, particularly when either epirubicin or oxaliplatin was present, respectively, seemed to be also time-dependent. Our overall data highlight the importance of BCL2L12 and DDC genes as emerging, future markers capable of predicting, staging and monitoring gastric cancer patients’ response to a more effective therapeutic treatment against gastric cancer. Part of the results of the present PhD Thesis has been published on the international research journal with reviewers ‘‘Biochemical and Biophysical Research Communications’’. [Florou D, Papadopoulos IN, Scorilas A. Biochem Biophys Res Commun. 010;391(1):214-8].
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Florou, Dimitra
- Φλώρου, Δήμητρα
Subjects
dc:subject × 13Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/26841